ArticleBlood2012
Treatment of erythropoietin deficiency in mice with systemically administered siRNA.
Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Review
- PHD1-3 oxygen sensors in vivo-lessons learned from gene deletions.Pflugers Archiv : European journal of physiology · 2024Review
- Administration of α-Klotho Does Not Rescue Renal Anemia in Mice.Frontiers in pediatrics · 2022Article
- The Endoplasmic Reticulum Cargo Receptor SURF4 Facilitates Efficient Erythropoietin Secretion.Molecular and cellular biology · 2020Article
- In Vivo RNAi-Mediated eIF3m Knockdown Affects Ribosome Biogenesis and Transcription but Has Limited Impact on mRNA-Specific Translation.Molecular therapy. Nucleic acids · 2020Article
- Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018Article
- Correction of Anemia in Chronic Kidney Disease WithFrontiers in pharmacology · 2018Article
- The EGLN-HIF OMolecular cell · 2017Review
- Anemia of Inflammation: A Review.The Medical clinics of North America · 2017Review
- The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer.Transactions of the American Clinical and Climatological Association · 2017Review
- Distinct subpopulations of FOXD1 stroma-derived cells regulate renal erythropoietin.The Journal of clinical investigation · 2016Article
- Renal epithelium regulates erythropoiesis via HIF-dependent suppression of erythropoietin.The Journal of clinical investigation · 2016Article
- Hypoxia Signaling Cascade for Erythropoietin Production in Hepatocytes.Molecular and cellular biology · 2015Article
- Anaemia in kidney disease: harnessing hypoxia responses for therapy.Nature reviews. Nephrology · 2015Review
- Suppression of erythropoiesis by dietary nitrate.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2015Article
- Development of lipoprotein(a) siRNAs for mechanism of action studies in non-human primate models of atherosclerosis.Journal of cardiovascular translational research · 2015Article
- Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice.Nature communications · 2014Article
- Silencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth In Vivo.Molecular therapy. Nucleic acids · 2014Article
- Hematological, hepatic, and retinal phenotypes in mice deficient for prolyl hydroxylase domain proteins in the liver.The American journal of pathology · 2014Article
- Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
Anemia linked to a relative deficiency of renal erythropoietin production is a significant cause of morbidity and medical expenditures in the developed world. Recombinant erythropoietin is expensive and has been linked to excess cardiovascular events. Moreover, some patients become refractory to erythropoietin because of increased production of factors such as hepcidin. During fetal life, the liver, rather than the kidney, is the major source of erythropoietin. In the present study, we show that it is feasible to reactivate hepatic erythropoietin production and suppress hepcidin levels using systemically delivered siRNAs targeting the EglN prolyl hydroxylases specifically in the liver, leading to improved RBC production in models of anemia caused by either renal insufficiency or chronic inflammation with enhanced hepcidin production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.